Aurobindo Pharma Limited
https://www.aurobindo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurobindo Pharma Limited
Deciphering Molnupiravir’s India Trial Discontinuation In Moderate COVID-19
Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?
As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.
Aurobindo’s Arrow Sees Advantages From New French Site
Aurobindo says a new logistics and industrial site opened in France by local subsidiary Laboratoire Arrow will support the firm’s growth plans in the French market.
Aurobindo Files First Biosimilar In Europe With Pegfilgrastim
Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Acrotech Biopharma, LLC
- APL
- Glaxo (India)
- TL Biopharmaceutical AG.